Duopharma Biotech made the announcement that the Government had accepted the tender offer from Duopharma Marketing and Biocon to supply the Insugen -Insulin Recombitant Human Formulations under the Ministry of Health’s procurement by way of direct negotiation (Revised LOA) upon the terms and conditions set out in the Revised Letter of Award.
Both Duopharma Marketing and Biocon have acknowledged receipt and acceptance of the Revised LOA on 25 April 2022 and submitted the said LOA to the Ministry of Health on 25 April 2022.
Under the revised LOA, Biocon is the manufacturer and supplier of the Insugen while Duopharma Marketing is the reseller appointed by Biocon to deliver the said products to MOH.
The Revised LOA shall be effective for a period of three years commencing on 29 April 2022 until 28 April 2025 with a total contract value of RM375,174,320.00. A binding contract would be created between the
MOH, Duopharma Marketing and Biocon upon acknowledgement of receipt and acceptance of the Revised LOA by Duopharma Marketing and Biocon.
